Korean Biotech Talks About U.S. Company Launch

Article

Pharmaceutical Executive

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

He spoke to Pharm Exec during a company event in New York City.

 

 

 

Recent Videos
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Marcel Botha, 10XBeta
Jennifer Kyle, Condor
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Kimberley Chiang, CoverMyMeds
Related Content
Stock.adobe.com

ABPI Restores Novo Nordisk’s Membership

Mike Hollan
March 21st 2025
Article

The pharmaceutical company had previously been subjected to a 2-year suspension.

Mike Ryan

The Challenges of Market Access in Europe that Pharma Companies Face: Q&A with Mike Ryan

Mike Hollan
March 20th 2025
Article

Pharma companies face unique challenges with market access in this region.

The NIH’s Role in New Drug Development

The NIH’s Role in New Drug Development

Mike Hollan
March 7th 2025
Article

Dr. Hernan Bazan, CEO of South Rampart Pharma, discusses his company’s current pipeline.

Stock.adobe.com

Eli Lilly Announces Four New Domestic Production Sites

Mike Hollan
March 3rd 2025
Article

Three of the new sites will focus primarily on producing ingredients for domestic usage.

Navigating the EU’s Joint Clinical Assessment

Navigating the EU’s Joint Clinical Assessment

Ruairi O’Donnell, PhD
February 13th 2025
Article

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

Navigating Cross-Border Pharma Deals: Key Trends and Lessons Out of China

Bruce Liu;Martin Slusarczyk, PhD;Selene Peng;Joki Wallace
February 12th 2025
Article

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.